Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 2-9 , January 2006

Biologic Basis for Combining Drugs With Radiation

  • George D. Wilson, BSc, PhD

      Affiliations

    • Department of Radiation Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
    • Corresponding Author InformationAddress reprint requests to Paul M. Harari, MD, University of Wisconsin Cancer Center, Department of Human Oncology, 600 Highland Avenue K4/332-3684, Madison, WI 53792.
    • ,
  • Søren M. Bentzen, PhD, DSc

      Affiliations

    • Department of Human Oncology, University of Wisconsin Medical School, Madison, WI.
    • ,
  • Paul M. Harari, MD

      Affiliations

    • Department of Human Oncology, University of Wisconsin Medical School, Madison, WI.

References 

  1. Bernier J , Hall EJ , Giaccia A . Radiation oncology (A century of achievements) . Nat Rev Cancer . 2004;4:737–747
  2. Bengtson EM , Rigas JR . A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer (Why we should look beyond platinum) . Semin Oncol . 1999;26:1–6
  3. Steel GG . Terminology in the description of drug-radiation interactions . Int J Radiat Oncol Biol Phys . 1979;5:1145–1150
  4. Steel GG , Peckham MJ . Exploitable mechanisms in combined radiotherapy-chemotherapy (the concept of additivity) . Int J Radiat Oncol Biol Phys . 1979;5:85–91
  5. Rosenberg B , VanCamp L , Trosko JE , et al.   Platinum compounds (a new class of potent antitumour agents) . Nature . 1969;222:385–386
  6. Eastman A , Barry MA . Interaction of trans-diamminedichloroplatinum(II) with DNA (Formation of monofunctional adducts and their reaction with glutathione) . Biochemistry . 1987;26:3303–3307
  7. Jones JC , Zhen WP , Reed E , et al.   Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells . J Biol Chem . 1991;266:7101–7107
  8. Fichtinger-Schepman AM , Baan RA , Luiten-Schuite A , et al.   Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding . Chem Biol Interact . 1985;55:275–288
  9. Plooy AC , van Dijk M , Berends F , et al.   Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II) . Cancer Res . 1985;45:4178–4184
  10. Siddik ZH . Cisplatin (Mode of cytotoxic action and molecular basis of resistance) . Oncogene . 2003;22:7265–7279
  11. Jordan P , Carmo-Fonseca M . Molecular mechanisms involved in cisplatin cytotoxicity . Cell Mol Life Sci . 2000;57:1229–1235
  12. Zhao H , Piwnica-Worms H . ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1 . Mol Cell Biol . 2001;21:4129–4139
  13. Damia G , Filiberti L , Vikhanskaya F , et al.   Cisplatinum and taxol induce different patterns of p53 phosphorylation . Neoplasia . 2001;3:10–16
  14. Agner J , Falck J , Lukas J , et al.   Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway . Exp Cell Res . 2005;302:162–169
  15. Wilson GD . Radiation and the cell cycle, revisited . Cancer Metastasis Rev . 2004;23:209–225
  16. Appella E , Anderson CW . Post-translational modifications and activation of p53 by genotoxic stresses . Eur J Biochem . 2001;268:2764–2772
  17. Losa JH , Parada Cobo C , Viniegra JG , et al.   Role of the p38 MAPK pathway in cisplatin-based therapy . Oncogene . 2003;22:3998–4006
  18. Schweyer S , Soruri A , Meschter O , et al.   Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation . Br J Cancer . 2004;91:589–598
  19. Mansouri A , Ridgway LD , Korapati AL , et al.   Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells . J Biol Chem . 2003;278:19245–19256
  20. Hennequin C , Favaudon V . Biological basis for chemo-radiotherapy interactions . Eur J Cancer . 2002;38:223–230
  21. Begg AC . Cisplatin and radiation (interaction probabilities and therapeutic possibilities) . Int J Radiat Oncol Biol Phys . 1990;19:1183–1189
  22. Myint WK , Ng C , Raaphorst GP . Examining the non-homologous repair process following cisplatin and radiation treatments . Int J Radiat Biol . 2002;78:417–424
  23. Gorodetsky R , Levy-Agababa F , Mou X , et al.   Combination of cisplatin and radiation in cell culture (Effect of duration of exposure to drug and timing of irradiation) . Int J Cancer . 1998;75:635–642
  24. Bartelink H , Kallman RF , Rapacchietta D , et al.   Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation . Radiother Oncol . 1986;6:61–74
  25. Kanazawa H , Rapacchietta D , Kallman RF . Schedule-dependent therapeutic gain from the combination of fractionated irradiation and cis-diamminedichloroplatinum (II) in C3H/Km mouse model systems . Cancer Res . 1988;48:3158–3164
  26. Dewit L . Combined treatment of radiation and cisdiamminedichloroplatinum (II) (A review of experimental and clinical data) . Int J Radiat Oncol Biol Phys . 1987;13:403–426
  27. Friedberg EC . DNA damage and repair . Nature . 2003;421:436–440
  28. Dolling JA , Boreham DR , Brown DL , et al.   Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae . Mutat Res . 1999;433:127–136
  29. Haveman J , Castro Kreder N , Rodermond HM , et al.   Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil . Oncol Rep . 2004;12:187–192
  30. Frit P , Canitrot Y , Muller C , et al.   Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II) (Role of Ku autoantigen) . Mol Pharmacol . 1999;56:141–146
  31. Turchi JJ , Henkels KM , Zhou Y . Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK . Nucleic Acids Res . 2000;28:4634–4641
  32. Raymond E , Chaney SG , Taamma A , et al.   Oxaliplatin (A review of preclinical and clinical studies) . Ann Oncol . 1998;9:1053–1071
  33. Hector S , Bolanowska-Higdon W , Zdanowicz J , et al.   In vitro studies on the mechanisms of oxaliplatin resistance . Cancer Chemother Pharmacol . 2001;48:398–406
  34. Pectasides D , Pectasides M , Farmakis D , et al.   Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer (A phase II study) . Gynecol Oncol . 2004;95:165–172
  35. Saris CP , van de Vaart PJ , Rietbroek RC , et al.   In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells . Carcinogenesis . 1996;17:2763–2769
  36. Scheeff ED , Briggs JM , Howell SB . Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin . Mol Pharmacol . 1999;56:633–643
  37. Fink D , Nebel S , Aebi S , et al.   The role of DNA mismatch repair in platinum drug resistance . Cancer Res . 1996;56:4881–4886
  38. Vaisman A , Varchenko M , Umar A , et al.   The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance (Correlation with replicative bypass of platinum-DNA adducts) . Cancer Res . 1998;58:3579–3585
  39. Espinosa M , Martinez M , Aguilar JL , et al.   Oxaliplatin activity in head and neck cancer cell lines . Cancer Chemother Pharmacol . 2005;55:301–305
  40. Cividalli A , Ceciarelli F , Livdi E , et al.   Radiosensitization by oxaliplatin in a mouse adenocarcinoma (Influence of treatment schedule) . Int J Radiat Oncol Biol Phys . 2002;52:1092–1098
  41. Minsky BD . Combined-modality therapy of rectal cancer with oxaliplatin-based regimens . Clin Colorectal Cancer . 2004;4(suppl 1):S29–S36
  42. Grem JL . 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development . Invest New Drugs . 2000;18:299–313
  43. Byfield JE . 5-Fluorouracil radiation sensitization–a brief review . Invest New Drugs . 1989;7:111–116
  44. Schlemmer HP , Becker M , Bachert P , et al.   Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy . Cancer Res . 1999;59:2363–2369
  45. Lawrence TS , Davis MA , Chang EY , et al.   Lack of dependence of 5-fluorodeoxyuridine-mediated radiosensitization on cytotoxicity . Radiat Res . 1995;143:281–285
  46. Nylen U , Cekan E , Jonasson GB , et al.   Effects of 5-fluorouracil on cell cycle arrest and toxicity induced by X-irradiation in normal mammalian cells . Cell Prolif . 2001;34:85–98
  47. Hughes LL , Luengas J , Rich TA , et al.   Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil (Effects on cell survival, DNA repair, and cell recovery) . Int J Radiat Oncol Biol Phys . 1992;23:983–991
  48. Bruso CE , Shewach DS , Lawrence TS . Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells . Int J Radiat Oncol Biol Phys . 1990;19:1411–1417
  49. Lawrence TS , Heimburger DK , Shewach DS . The effects of leucovorin and dipyridamole on fluoropyrimidine-induced radiosensitization . Int J Radiat Oncol Biol Phys . 1991;20:377–381
  50. Davis MA , Tang HY , Maybaum J , et al.   Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression . Int J Radiat Biol . 1995;67:509–517
  51. Lawrence TS , Davis MA , Loney TL . Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation . Cancer Res . 1996;56:3203–3206
  52. Zellars RC , Naida JD , Davis MA , et al.   Effect of p53 overexpression on radiation sensitivity of human colon cancer cells . Radiat Oncol Investig . 1997;5:43–49
  53. Nishimura G , Terada I , Kobayashi T , et al.   Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy . Oncol Rep . 2002;9:479–482
  54. Hotta T , Taniguchi K , Kobayashi Y , et al.   Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue . Oncol Rep . 2004;12:539–541
  55. Sawada N , Ishikawa T , Sekiguchi F , et al.   X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts . Clin Cancer Res . 1999;5:2948–2953
  56. Barton-Burke M . Gemcitabine (A pharmacologic and clinical overview) . Cancer Nurs . 1999;22:176–183
  57. Plunkett W , Huang P , Xu YZ , et al.   Gemcitabine (metabolism, mechanisms of action, and self-potentiation) . Semin Oncol . 1995;22:3–10
  58. Plunkett W , Huang P , Gandhi V . Preclinical characteristics of gemcitabine . Anticancer Drugs . 1995;6(suppl 6):7–13
  59. Shewach DS , Lawrence TS . Gemcitabine and radiosensitization in human tumor cells . Invest New Drugs . 1996;14:257–263
  60. Shewach DS , Hahn TM , Chang E , et al.   Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells . Cancer Res . 1994;54:3218–3223
  61. Lawrence TS , Chang EY , Hahn TM , et al.   Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) . Clin Cancer Res . 1997;3:777–782
  62. van Putten JWG , Groen HJM , Smid K , et al.   End-joining deficiency and radiosensitization induced by gemcitabine . Cancer Res . 2001;61:1585–1591
  63. Wachters FM , van Putten JW , Maring JG , et al.   Selective targeting of homologous DNA recombination repair by gemcitabine . Int J Radiat Oncol Biol Phys . 2003;57:553–562
  64. Robinson BW , Im MM , Ljungman M , et al.   Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells . Cancer Res . 2003;63:6935–6941
  65. Lawrence TS , Blackstock AW , McGinn C . The mechanism of action of radiosensitization of conventional chemotherapeutic agents . Semin Radiat Oncol . 2003;13:13–21
  66. Lawrence TS . Radiation sensitizers and targeted therapies . Oncology (Huntingt) . 2003;17:23–28
  67. Ma BB , Bristow RG , Kim J , et al.   Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents . J Clin Oncol . 2003;21:2760–2776
  68. Mendelsohn J , Baselga J . The EGF receptor family as targets for cancer therapy . Oncogene . 2000;19:6550–6565
  69. Haffty BG . Molecular and genetic markers in the local-regional management of breast cancer . Semin Radiat Oncol . 2002;12:329–340
  70. Liang K , Ang KK , Milas L , et al.   The epidermal growth factor receptor mediates radioresistance . Int J Radiat Oncol Biol Phys . 2003;57:246–254
  71. Huang SM , Bock JM , Harari PM . Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck . Cancer Res . 1999;59:1935–1940
  72. Chakravarti A , Dicker A , Mehta M . The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas (A review of preclinical and correlative clinical data) . Int J Radiat Oncol Biol Phys . 2004;58:927–931
  73. Gee JM , Nicholson RI . Expanding the therapeutic repertoire of epidermal growth factor receptor blockade (Radiosensitization) . Breast Cancer Res . 2003;5:126–129
  74. Baumann M , Krause M . Targeting the epidermal growth factor receptor in radiotherapy (Radiobiological mechanisms, preclinical and clinical results) . Radiother Oncol . 2004;72:257–266
  75. Harari PM . Epidermal growth factor receptor inhibition strategies in oncology . Endocr Relat Cancer . 2004;11:689–708
  76. Harari PM , Huang SM . Combining EGFR inhibitors with radiation or chemotherapy (Will preclinical studies predict clinical results?) . Int J Radiat Oncol Biol Phys . 2004;58:976–983
  77. Wells A . EGF receptor Int . J Biochem Cell Biol . 1999;31:637–643
  78. Magne N , Fischel JL , Dubreuil A , et al.   ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity (Rational basis for a new combination therapy with capecitabine) . Clin Cancer Res . 2003;9:4735–4742

PII: S1053-4296(05)00045-7

doi: 10.1016/j.semradonc.2005.08.001

Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 2-9 , January 2006

Article Tools

* Image Usage & Resolution